Renaissance Capital logo

Athira Pharma Priced, Nasdaq: ATHA

Phase 2/3 biotech targeting the novel HGF/MET pathway for Alzheimer's.

Industry: Health Care

Latest Trade: $16.25 0.00 (0.0%)

First Day Return: +0.6%

Return from IPO: -4.4%

Industry: Health Care

We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Our approach is designed to augment neuronal growth factor signaling through the HGF/MET, a naturally occurring regenerative system. Our pipeline is built from our proprietary drug discovery platform, or ATH platform, and consists of a series of small molecules that are designed to target either (1) the central nervous system, or CNS, by crossing the blood brain barrier, or BBB, or (2) the peripheral nervous system. Our lead candidate, ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule HGF/MET activator. In our Phase 1a and Phase 1b clinical trials, ATH-1017 for the treatment of Alzheimer’s disease, or AD, was well tolerated with no serious adverse events. These clinical trials recruited 88 subjects, including 11 subjects with mild-to-moderate AD. Nonclinical studies and Phase 1 clinical trials with ATH-1017 demonstrated improvements in brain network activity indicating potentially positive effects on brain function.
more less
IPO News for Athira Pharma
more
IPO Data
IPO File Date 08/26/2020
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 12.0
Deal Size ($mm) $204
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/17/2020
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 12.0
Deal Size ($mm) $204
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Seattle, WA
Founded 2011
Employees 15
Website www.athira.com